Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare Biotechnology

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc

Bullboard Posts

Comment by TheRock07on Oct 06, 2016 8:14pm

449 Views

Post# 25320342

RE:Over sold...

Oversold is hardly a fitting descriptor .

Hard book is $8 per share, mostly cash and liquid investments , and no debt .

So for just over $1 per share, we are getting all of future benefits of a wide variety of commercial drugs, the ability to cherry pick at an early stage, disruptive medical drugs/ technologies, equity ownership in several undervalued pharmas, and perhaps the best management team on the bourses.

I buy a few more on days like these..

Bullboard Posts

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal